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from the 200,000-cohort claim database of the National Health
Insurance (NHI). The prices, total amounts and the market
shares in different levels of health care setting were analyzed.
RESULTS: Among 5 SSRI antidepressants, ﬂuoxetine used
43.5% of the total SSRI expenditures. Compared with other
SSRIs, ﬂuoxetine also had the most number of different generic
items, the shortest time lags, higher prices of the generics, and the
fastest replacement rate by other generics. In 1997 the total
expenditure of ﬂuoxetine in medical centers and the district
hospitals was 82.8% and 17.2% in the local hospital and the
clinics. After the ﬁrst entry the original drug 15 years ago, the
market share of the original drug had shrunk to 1.46%. In
general the prices of original drugs fell 0–6.4% in the ﬁrst year
while the ﬁrst generic entered the market with the 80–87.7%
original price. CONCLUSION: This study presented the proﬁles
of generic competitions of SSRI antidepressants, which could
provide an approach for both policy maker and industry to
investigate the drug usage at national level. Except for ﬂuoxetine,
the generic market of SSRI antidepressants seem still promising.
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OBJECTIVE: To examine Texas Medicaid prescribers’ percep-
tions of the prior authorization (PA) process for non-preferred
psychotherapeutics among patients with severe mental illness.
METHODS: A 54-item survey instrument was used to assess the
perceived burden of prior authorization for psychotherapeutics
(BoPAP) held among mental health prescribers. The BoPAP
instrument was developed based on responses from three expert
focus group panels and was comprised of three sub-scales
(‘patient care process and outcomes’, ‘system/societal costs’, and
‘administrative issues’). The survey was pre-tested and then
mailed to 1650 Texas prescribers of psychiatric medications.
Exploratory factor analyses (EFA) techniques were used to reﬁne
the BoPAP scale(s). RESULTS: The study yielded an 18.3%
(n = 237) response rate with a majority of respondents being
family physicians (43%). Most (95.4%) reported treating
Medicaid patients. Respondents prescribed an average of 64
(Median = 40, SD = 102) Medicaid prescriptions per week with
17.8% requiring PA for non-preferred psychotherapeutics.
Overall, prescribers reported PA as a moderate burden (BoPAP
scale mean = 3.90, SD = 1.48; possible range 1 = ‘low burden’ to
5 = ‘high burden’) to their practice. Regarding the ‘administra-
tive issues’ subscale, respondents reported a moderate to strong
burden (Mean = 4.5, SD = 0.54); prescribers felt the PA process
led to uncompensated administrative time (Mean = 4.56,
SD = 0.63) and introduced an extra step in providing patient
care (Mean = 4.55, SD = 0.65). Prescribers reported a moderate
burden (Mean = 3.90, SD = 1.48) on the ‘patient care processes
and outcomes’ subscale, citing the PA process added another
level of bureaucracy (Mean = 4.51, SD = 0.64), led to patient
frustration (Mean = 4.21, SD = 0.77), and took focus away
from patient care (Mean = 4.08, SD = 0.87). The third sub-
scale, ‘system/social costs,’ was less burdensome (Mean = 3.29,
SD = 0.67) among respondents. CONCLUSION: Overall, Texas
mental health providers felt that the PA process negatively
impacted the quality and continuity of care they provide to their
mentally ill patients. Future studies should be conducted in other
states to determine the utility of the BoPAP instrument.
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OBJECTIVE: To describe the temporal prescribing patterns of
selective serotonin reuptake inhibitors (SSRI) and similar antide-
pressant medications among pediatric patients covered through a
state child health insurance and Medicaid program from 2000
through 2007. METHODS: Administrative claims data from
the health insurance programs of the Arkansas Department of
Human Services were examined from July 2000 through June
2007. Continuously eligible patients under age 18 were identiﬁed
in 14 6-month time periods. Pharmacy claims data identiﬁed all
covered recipients receiving a prescription for any antidepressant
obtained from an outpatient pharmacy. Considering published
data on use in children, antidepressant medications were char-
acterized as FDA approved, supported with evidence, lacking
adequate evidence, or relatively contraindicated. RESULTS:
Prevalence of SSRI and similar product use was 20 per 1000
children aged 6 to 12 years, and 48 per 1000 children aged 12 to
18 years in the initial 6 month period. Use peaked for 6 to 12
year old children at a rate of 24 per 1000 in the last half of 2002,
and for 12 to 18 year old children at a rate of 63 per thousand in
the ﬁrst half of 2004. In the ﬁrst half of 2007, the prevalence of
use was 16 per 1000 and 53 per 1000 for the younger and older
age groups respectively. Since 2002, the proportion of SSRI prod-
ucts with minimal or no supporting evidence of safety or effec-
tiveness in children increased from 20% to more than 45% of
patient treatments. CONCLUSION: Decreases in use of SSRI
and similar medications were seen among children covered by
Arkansas medical assistance plans after FDA advisories were
issued in 2003 and 2004. Additionally, young patients appear to
be increasingly treated with SSRI and similar medications having
minimal or no data supporting safety and effectiveness in chil-
dren or adolescents.
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OBJECTIVE: Anecdotal evidence suggests that prescribing of
ADHD therapies among children in the United States decreases
over the summer months when children and adolescents are out
of school. METHODS: We used retail pharmacy prescription
data to investigate monthly and annual ADHD prescribing
trends from January 2003 to October 2007 to determine if there
is any variation in prescribing, especially over the summer
months. The prescription data was obtained from Verispan’s
Vector One National (VONA), which captures nearly half of all
prescription activity in the United States. The Verispan prescrip-
tion data is age-speciﬁc; thus we were able to examine monthly
total prescriptions for two age groups: 0 to 17 years and 18 years
and older. RESULTS: There was a signiﬁcant dip in total pre-
scription volume in the summer months for the 0–17 age group.
The magnitude of the seasonality observed between May and
July ranged from a 22% to 29% decrease in total prescriptions,
depending on the year. In contrast, total prescriptions in the 18
and older age group have been rising steadily since January 2003,
and there is no observed seasonality. CONCLUSION: Our ﬁnd-
ings suggest that as many as 30% of children and adolescents use
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